Fundraising Fox

Aclaris Therapeutics

5 known investors

aclaristx.com ↗

Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases. The company's clinical and preclinical pipeline includes candidates in development for severe asthma, atopic dermatitis, and T-cell-mediated autoimmune conditions.

BiotechHealthtechMedical Devices

Investors · 5

Aisling CapitalNew York
APERTURE Venture PartnersBoston
F-Prime Capital PartnersBoston
Sofinnova VenturesMenlo Park
Vivo CapitalreportedPalo Alto

In the news